

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Certolizumab pegol for psoriasis

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

In previous technology appraisals on psoriasis, it has been highlighted that the Psoriasis Area and Severity Index (PASI) can underestimate disease severity in those with black or brown skin, and that the Dermatology Life Quality Index (DLQI) has limited validity in some people, and may also miss anxiety and depression.

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

In previous technology appraisals on psoriasis, the committee has included a recommendation that when using the PASI, healthcare professionals should take into account skin colour and how this could affect the PASI score, and make any adjustments they consider appropriate. It also included a recommendation than when using the DLQI, healthcare professionals should take into account any physical, psychological, sensory or learning disabilities, or communication difficulties, that could affect the responses to the DLQI and make any adjustments they consider appropriate.

3. Has any change to the draft scope been agreed to highlight potential equality issues?
No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No

Approved by Associate Director (name): Melinda Goodall

Date: 14/06/2016